80 Participants Needed

64Cu-FBP8 PET-CT Imaging for Blood Clots

TW
MT
Overseen ByMamary T Kone, MD, MPH
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing a new imaging tool that helps doctors see fresh blood clots in patients with PE and DVT. It uses a special substance that binds to the clots, making them visible on a PET scan. This could improve diagnosis, especially for patients with kidney or lung problems.

Who Is on the Research Team?

TW

Tilo Winkler, PhD

Principal Investigator

Massachusetts General Hospital

Are You a Good Fit for This Trial?

This trial is for adults over 18 with a recent diagnosis of pulmonary embolism or deep vein thrombosis confirmed by CT scans. Participants must be able to lie flat for 45 minutes and have adequate kidney function. Pregnant women, those exceeding weight limits for PET imaging, or individuals exposed to high levels of radiation in the past year are excluded.

Inclusion Criteria

I am 18 or older and have a confirmed pulmonary embolism.
I received a special injection within 3 days of being diagnosed.

Exclusion Criteria

I cannot lie flat for 45 minutes due to a condition like back pain or arthritis.
My eligibility is not affected by my race, sex, or ethnicity.
I am not pregnant or breastfeeding, confirmed by a test.
See 9 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive 64Cu-FBP8 and undergo PET-CT imaging to assess thrombus location and clot burden

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after imaging

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • 64Cu-FBP8
  • PET-CT Imaging
Trial Overview The study tests a new PET scan probe called 64Cu-FBP8 designed to detect fresh blood clots in lungs and veins. It aims to see how well this probe works compared to current diagnostic methods within three days of clot diagnosis.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Acute pulmonary embolismExperimental Treatment2 Interventions
Subjects will receive 64Cu-FBP8 and undergo PET-CT imaging.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Peter David Caravan

Lead Sponsor

Trials
1
Recruited
80+

Peter Caravan

Lead Sponsor

Trials
2
Recruited
140+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security